Gene-edited hypoimmune islets as a cure for type 1 diabetes: a review of the immunological challenges.
TL;DR
Current preclinical and clinical evidence from 2019 to 2026 for gene-edited hypoimmune islets is critically evaluated, highlighting key immunological vulnerabilities that may emerge over time and whether these long-term challenges can be overcome.
Abstract
INTRODUCTION Islet transplantation has long been considered a potential long-term treatment for type 1 diabetes mellitus (T1DM); however, the need for systemic immunosuppression has limited its clinical utility due to associated toxicity. Gene-edited hypoimmune islets represent a promising immunosuppression-free alternative. Recent first-in-human data demonstrating short-term engraftment and C-peptide production without immunosuppression, with 12-week immune monitoring and extended 14-month follow-up, provide an important proof-of-concept. However, whether short-term immune evasion can translate into durable long-term graft survival remains unclear. AREAS COVERED We critically evaluate current preclinical and clinical evidence from 2019 to 2026 for gene-edited hypoimmune islets, highlighting key immunological vulnerabilities that may emerge over time. EXPERT OPINION The central question is no longer whether these islets can evade acute rejection, but whether they can sustain this evasion and efficacy long-term against the human immune system. Several theoretical mechanisms may contribute to delayed graft injury: indirect allorecognition (particularly non-HLA antibody formation), persistence of autoreactive immune memory, β-cell stress-induced neoantigen formation, and susceptibility to viral infection. Durable graft survival will likely require multimodal approaches combining gene-edited islets with adjunct immunomodulation (e.g. teplizumab, low-dose ATG, tegoprubart) and metabolic support. If these long-term challenges can be overcome, gene-edited hypoimmune islets could transform T1DM treatment paradigms.
